Immunitas Therapeutics procures $58m Series B
Immunitas Therapeutics, a single cell genomics-based therapeutics company, has secured $58 million in Series B financing.
18 August 2021•1 min read
Immunitas Therapeutics, a single cell genomics-based therapeutics company, has secured $58 million in Series B financing.
New AI threats are fueling VC investment in cybersecurity
22 October 2026 · 4 mins read
Inspired Capital holds quick close on $450m for Fund IV
20 October 2026 · 4 mins read
Inovia hits $200m in first close for sixth early-stage fund
19 October 2026 · 4 mins read
San Joaquin County to slow venture commitments
15 October 2026 · 2 mins read
DOWNLOAD: Fundraising holds steady in Q3
14 October 2026 · 2 mins read
Why Endeavor Catalyst is betting big on Southeast Asia
8 October 2026 · 4 mins read
Dig's new fund bets on infrastructure built around foundation models
6 October 2026 · 4 mins read
